• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确定“边界可切除”胰腺癌——对 30 种灰度的全球评估。

Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey.

机构信息

Department of Upper Gastrointestinal Surgery, St Vincent's Hospital Melbourne, Melbourne, Australia; Department of Surgery, The University of Melbourne, St Vincent's Hospital, Melbourne, Australia.

Cancer Research Program, School of Public Health & Preventive Medicine Monash University, Melbourne, Australia.

出版信息

HPB (Oxford). 2023 Nov;25(11):1393-1401. doi: 10.1016/j.hpb.2023.07.883. Epub 2023 Jul 22.

DOI:10.1016/j.hpb.2023.07.883
PMID:37558564
Abstract

BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor prognosis. Accurate preoperative assessment using computed tomography (CT) to determine resectability is crucial in ensuring patients are offered the most appropriate therapeutic strategy. Despite the use of classification guidelines, any interobserver variability between reviewing surgeons and radiologists may confound decisions influencing patient treatment pathways.

METHODS

In this multicentre observational study, an international group of 96 clinicians (42 hepatopancreatobiliary surgeons and 54 radiologists) were surveyed and asked to report 30 pancreatic CT scans of pancreatic cancer deemed borderline at respective multidisciplinary meetings (MDM). The degree of interobserver agreement in resectability among radiologists and surgeons was assessed and subgroup regression analysis was performed.

RESULTS

Interobserver variability between reviewers was high with no unanimous agreement. Overall interobserver agreement was fair with a kappa value of 0.32 with a higher rate of agreement among radiologists over surgeons.

CONCLUSION

Interobserver variability among radiologists and surgeons globally is high, calling into question the consistency of clinical decision making for patients with PDAC and suggesting that central review may be required for studies of neoadjuvant or adjuvant approaches in future as well as ongoing quality control initiatives, even amongst experts in the field.

摘要

背景

胰腺导管腺癌(PDAC)是一种侵袭性癌症,预后不良。使用计算机断层扫描(CT)进行准确的术前评估以确定可切除性对于确保为患者提供最合适的治疗策略至关重要。尽管使用了分类指南,但审查外科医生和放射科医生之间的任何观察者间差异都可能使影响患者治疗途径的决策复杂化。

方法

在这项多中心观察性研究中,一组 96 名国际临床医生(42 名肝胆胰外科医生和 54 名放射科医生)接受了调查,并被要求报告在各自的多学科会议(MDM)上被认为是边缘性的 30 例胰腺 CT 扫描胰腺癌。评估了放射科医生和外科医生之间在可切除性方面的观察者间一致性,并进行了亚组回归分析。

结果

审稿人之间的观察者间差异很大,没有一致意见。总体观察者间一致性为中等,kappa 值为 0.32,放射科医生之间的一致性高于外科医生。

结论

全球范围内放射科医生和外科医生之间的观察者间差异很大,这使得对 PDAC 患者的临床决策的一致性受到质疑,并表明即使在该领域的专家中,未来也可能需要对新辅助或辅助方法进行研究以及正在进行的质量控制计划,需要进行中央审查。

相似文献

1
Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey.确定“边界可切除”胰腺癌——对 30 种灰度的全球评估。
HPB (Oxford). 2023 Nov;25(11):1393-1401. doi: 10.1016/j.hpb.2023.07.883. Epub 2023 Jul 22.
2
High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.高分辨率胰腺 CT 评估胰腺导管腺癌可切除性:一项多中心前瞻性研究。
Eur Radiol. 2023 Sep;33(9):5965-5975. doi: 10.1007/s00330-023-09584-2. Epub 2023 Mar 29.
3
Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.人工智能在评估胰腺癌患者 CT 血管侵犯和肿瘤可切除性中的应用。
Eur Radiol Exp. 2024 Feb 12;8(1):18. doi: 10.1186/s41747-023-00419-9.
4
Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement.术前 CT 对胰腺癌可切除性的分类:观察者间一致性。
Radiology. 2019 Nov;293(2):343-349. doi: 10.1148/radiol.2019190422. Epub 2019 Sep 10.
5
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.局部进展期胰腺导管腺癌可切除性判断的共识——Conko-007 多中心试验结果。
BMC Cancer. 2019 Oct 22;19(1):979. doi: 10.1186/s12885-019-6148-5.
6
Assessment of resectability of pancreatic cancer using novel immersive high-performance virtual reality rendering of abdominal computed tomography and magnetic resonance imaging.利用新型沉浸式高性能虚拟现实技术对腹部 CT 和 MRI 进行胰腺癌可切除性评估。
Int J Comput Assist Radiol Surg. 2024 Sep;19(9):1677-1687. doi: 10.1007/s11548-023-03048-0. Epub 2024 Jan 22.
7
Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot.对比影像学 CT 扫描报告在符合国际共识指南的标准下,对胰腺腺癌进行手术可切除性评估:维多利亚州的一项试点研究。
ANZ J Surg. 2022 Oct;92(10):2565-2570. doi: 10.1111/ans.17999. Epub 2022 Aug 24.
8
Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.胰腺癌分期:可切除、边界可切除和不可切除疾病。
Abdom Radiol (NY). 2018 Feb;43(2):301-313. doi: 10.1007/s00261-017-1410-2.
9
Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.局部进展期和可切除边界胰腺癌 FOLFIRINOX 治疗后的手术:CT 上肿瘤衰减增加与 R0 切除相关。
Eur Radiol. 2018 Oct;28(10):4265-4273. doi: 10.1007/s00330-018-5410-6. Epub 2018 Apr 20.
10
White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.美国腹部放射学会胰腺导管腺癌疾病聚焦专家组关于胰腺导管腺癌的白皮书:第一部分,AJCC 分期系统、NCCN 指南和交界可切除疾病。
Abdom Radiol (NY). 2020 Mar;45(3):716-728. doi: 10.1007/s00261-019-02289-5.

引用本文的文献

1
Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer.持续未能为胰腺癌患者提供符合指南的治疗。
Cancers (Basel). 2025 Jan 7;17(2):170. doi: 10.3390/cancers17020170.
2
SCANPatient: study protocol for a multi-centre, batched, stepped wedge, comparative effectiveness, randomised clinical trial of synoptic reporting of computerised tomography (CT) scans assessing cancers of the pancreas.SCAN 患者:一项多中心、分批、阶梯式、比较有效性、随机临床试验的研究方案,用于综合报告评估胰腺癌症的计算机断层扫描 (CT) 扫描。
Trials. 2024 Jun 17;25(1):388. doi: 10.1186/s13063-024-08196-5.
3
Inter-reader agreement of pancreatic adenocarcinoma resectability assessment with photon counting versus energy integrating detector CT.
基于能谱探测器 CT 与常规探测器 CT 评估胰腺腺癌可切除性的读者间一致性研究。
Abdom Radiol (NY). 2024 Sep;49(9):3149-3157. doi: 10.1007/s00261-024-04298-5. Epub 2024 Apr 17.
4
Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.基于肿瘤-血管相互作用和 CA19-9 水平检测可切除胰腺癌的新辅助治疗候选者:一项回顾性队列研究。
Int J Surg. 2024 May 1;110(5):2883-2893. doi: 10.1097/JS9.0000000000001184.
5
Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma.分期计算机断层扫描参数可预测可切除性胰腺导管腺癌行胰十二指肠切除术时静脉切除的必要性。
Diagnostics (Basel). 2024 Jan 7;14(2):135. doi: 10.3390/diagnostics14020135.
6
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.当前关于胰腺导管腺癌外科治疗的争议话题:关于可切除边缘、局部进展期以及同时性或异时性寡转移瘤外科治疗的叙述性综述
J Clin Med. 2023 Oct 11;12(20):6461. doi: 10.3390/jcm12206461.